Your experience on this site will be improved by allowing cookies.
N E W S
Ruxolitinib cream (Opzelura) has just obtained reimbursement in France. It will initially be direct access, that is to say that all dermatologists will be able to prescribe it but it will have to be picked up initially from hospital pharmacies.
Numerous ongoing and future trials for diffuse vitiligo (at least 5% of the face AND 5% of the body affected).
With the identification of biologic and molecular mechanisms involved in the pathophysiology of vitiligo, new treatments are currently developed. Among them, systemic treatments for patients with widespread and/or very active disease, but also topical approaches for repigmenting patches resistant to current treatments. These new treatments are first proposed in clinical trials. These clinical trials are highly supervised and allow proposing the latest advances in optimum safety conditions. At the time, supporting fundamental and translational researches remains mandatory to better understand the mechanisms involved in the depigmentation of the skin but also to study the pathways that allow melanocytes to recolonize the affected skin for repigmenting the lesional patches.